FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The late-breaking U.S. multicenter admIRE clinical trial at the Heart Rhythm Society 2024 meeting, showed positive data on the long-term safety and effectiveness of the the Biosense Webster Varipulse pulsed field ablation (PFA) system in patients with paroxysmal atrial fibrillation. #HRS #HRS2024 #PFA

Johnson & Johnson MedTech's Varipulse PFA catheter. Image courtesy of Johnson & Johnson MedTech.

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.

NP leader scores $750,000 grant with hopes of boosting lung cancer screening uptake by the thousands

Lisa Carter-Bawa, PhD, MPH

Lisa Carter-Bawa, PhD, MPH, director of the Hackensack Meridian Center for Discovery and Innovation’s Cancer Prevention Precision Control Institute. 

Those involved plan to hire a community health worker and care navigator to help shepherd underserved patients through the screening process.